TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26303336

Group type: EXPERIMENTAL
Intervention: Aclidinium and formoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aclidinium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aclidinium plus formoterol
Number of subjects: 0
Study: 23657857

Group type: COMPARATOR
Intervention: Placebo (PL) + L-NAME
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Placebo (PL) + L-NAME in DM
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Losartan (LOS) pretreatment + L-NAME in DM
Number of subjects: 23
Study: 20510977

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 98

Group type: COMPARATOR
Intervention: In-person assessments
Number of subjects: 98
Study: 19192659

Group type: COMPARATOR
Intervention: 10,000 IU erythropoetin beta three times a week (group A)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 20,000 IU erythropoetin beta twice a week (group B)
Number of subjects: 119
Study: 16875904

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with the ARB valsartan
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 12657339

Group type: EXPERIMENTAL
Intervention: Individual counseling intervention (7 sessions over 9 months) based on PACE protocols
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (received written information about lifestyle factors)
Number of subjects: 299
Study: 10638587

Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 119
Study: 9365551

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study: 1411317

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 89
Study: 3516163

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31667693

Group type: EXPERIMENTAL
Intervention: Sterile carbon particle suspension (SCPS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: India ink
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: SCPS
Number of subjects: 94
Study: 28425497

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg (p.o.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26072190

Group type: EXPERIMENTAL
Intervention: Informed consent training
Number of subjects: 80
Study: 23243228

Group type: EXPERIMENTAL
Intervention: Pleasant contact (PL) - chicks stroked gently for 30 s once daily from d 1 to 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpleasant contact (UNPL) - chicks suspended by legs and exposed to noise for 15 s once daily from d 1 to 28
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control - no physical or visual contact with humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PL-UNPL - chicks subjected to PL from d 1 to 14 and UNPL from d 15 to 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UNPL-PL - chicks subjected to UNPL from d 1 to 14 and PL from d 15 to 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PL and PL-UNPL treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum creatine kinase activity of PL
Number of subjects: 0
Study: 21991728

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% and morphine 0.2 mg/mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% and morphine 0.2 mg/mL and Xefocam 0.8 mg/mL
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study: 19960134

Group type: EXPERIMENTAL
Intervention: Diuretic-based treatment (n=20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB)-based treatment (n=18)
Number of subjects: 38
Study: 16901484

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) for >or=3 weeks
Number of subjects: 39
Study: 14670569

Group type: EXPERIMENTAL
Intervention: Cognitive battery including arithmetical tests (addition, subtraction, multiplication, division) and tests of understanding of numerosity and quantity (cognitive estimation, estimation, comparison, bisection, subitizing/counting)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control subjects (13 individuals)
Number of subjects: 25
Study: 12383150

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Moderate alcohol use
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Selected medical conditions (diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease (CVD), osteoporosis, arthritis, and cancer)
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Low cognitive function
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Coronary heart disease
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Cerebrovascular disease (CVD)
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Osteoporosis
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Arthritis
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 2581
Study: 9878104

Group type: EXPERIMENTAL
Intervention: Event-monitoring task
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Event-mapping task
Number of subjects: 8
Study: 8031275

Group type: EXPERIMENTAL
Intervention: Affected eyes at baseline
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Affected eyes at 6 months
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Affected eyes at 1 year
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Fellow eyes at baseline
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Fellow eyes at 6 months
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Fellow eyes at 1 year
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Patients with retrochiasmal visual field defect
Number of subjects: 448

Group type: COMPARATOR
Intervention: Other patients in the trial
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Binocular analysis
Number of subjects: 448
Study: 3042576

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d.)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.i.d. + placebo b.i.d.)
Number of subjects: 56
Study: 31039386

Group type: EXPERIMENTAL
Intervention: 45S5 Bioglass
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fluoride 4-minutes
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fluoride 24-Hours
Number of subjects: 66

Group type: COMPARATOR
Intervention: Temp (Caviton)
Number of subjects: 66
Study: 28433923

Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 17

Group type: COMPARATOR
Intervention: Apple juice
Number of subjects: 17
Study: 24280956

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no plasma rich in growth factors)
Number of subjects: 0
Study: 23447607

Group type: EXPERIMENTAL
Intervention: Blocks highly biased toward punishment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DA antagonist administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Predetermined maximal acceleration (MA) execution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting neurophysiological variability
Number of subjects: 0
Study: 21303308

Group type: EXPERIMENTAL
Intervention: VX‐770
Number of subjects: 0
Study: 19825284

Group type: EXPERIMENTAL
Intervention: Dexamethasone (intravenously once a day for 4 weeks, then orally once daily for another 4 weeks)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (intravenously once a day for 5 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (standard anti-tuberculosis drugs only)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: All groups (dexamethasone, methylprednisolone, control)
Number of subjects: 97
Study: 16715530

Group type: EXPERIMENTAL
Intervention: NT measurement >or= 95th centile for crown‐rump length
Number of subjects: 16383

Group type: EXPERIMENTAL
Intervention: NT measurement >or= 3.0 mm
Number of subjects: 16383

Group type: EXPERIMENTAL
Intervention: NT measurement >or= 3.5 mm
Number of subjects: 16383
Study: 14666387

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIBI SPET
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: (131)I scintigraphy
Number of subjects: 19
Study: 11766940

Group type: EXPERIMENTAL
Intervention: Estimation of sizes of common objects from memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimation of sizes and distances of objects displayed in front of subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Good distance information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Far distances
Number of subjects: 0
Study: 9264417

Group type: EXPERIMENTAL
Intervention: Propranolol (8 mg cumulative dose or maximum heart rate reduction of 25%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (dobutamine stress test without propranolol)
Number of subjects: 17
Study: 8282676

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3234607

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 12
Study: 29576125

Group type: EXPERIMENTAL
Intervention: PECs blocks (levobupivacaine 0.25%, 10 ml PECs I and 20 ml PECs II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LA infusion (levobupivacaine 0.1% at 10 ml h‐1 for 24 h)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both PECs and LA infusion
Number of subjects: 45
Study: 28410749

Group type: EXPERIMENTAL
Intervention: K-877 (pemafibrate) 0.1, 0.2, and 0.4 mg/day in combination with pitavastatin for 12 weeks
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: K-877 (pemafibrate) 0.2 mg/day (fixed dose) and 0.2 (0.4) mg/day (conditional up-titration) in combination with any statin for 24 weeks
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: K-877 add-on therapy
Number of subjects: 611

Group type: COMPARATOR
Intervention: K-877 combination therapy
Number of subjects: 611
Study: 25535783

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide for three hours a day for three weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (nonsmokers)
Number of subjects: 60
Study: 22370870

Group type: EXPERIMENTAL
Intervention: Xiaopi-I
Number of subjects: 134

Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 134
Study: 20494730

Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol sublingually
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1422
Study: 18179785

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 16942565

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 200,000 SQ-U, 5 days a week for up to 18 months
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with tree pollen extract, accumulated weekly dose of 24,000 SQ-U, 5 days a week for up to 18 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 15385016

Group type: EXPERIMENTAL
Intervention: remifentanil + propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: propofol alone
Number of subjects: 20
Study: 11421892

Group type: EXPERIMENTAL
Intervention: Health complications during pregnancy
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Health complications during labor or delivery
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Child illness or health complications during the first week of life
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Birth weight of < 2.5 kg
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Early or threatened labor (ICD: 644)
Number of subjects: 4065

Group type: EXPERIMENTAL
Intervention: Malposition or malpresentation of the fetus (ICD: 652)
Number of subjects: 4065
Study: 9241010

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day
Number of subjects: 135

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 8390528

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once a day
Number of subjects: 80
Study: 2942164

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200
Study: 31856984

Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with viscosynechialysis and trabeculotomy (phaco-viscosynechialysis group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Phacoemulsification combined with trabeculectomy (phacotrabeculectomy group)
Number of subjects: 59
Study: 28930850

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) combined with intraoperative cell salvage (ICS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intraoperative cell salvage (ICS) alone (Control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ANH
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 24983306

Group type: EXPERIMENTAL
Intervention: Valganciclovir or ganciclovir
Number of subjects: 291
Study: 23418635

Group type: EXPERIMENTAL
Intervention: Complete cochlear implantation (activation of all electrodes)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Activation of basal electrode pairs (E12) nearest to the round window
Number of subjects: 7

Group type: COMPARATOR
Intervention: Non-implanted control group
Number of subjects: 7
Study: 20847081

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study: 19294678

Group type: EXPERIMENTAL
Intervention: Oral azithromycin, 500 mg per day for 3 days before amniocentesis
Number of subjects: 34923

Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 34923
Study: 17378260

Group type: EXPERIMENTAL
Intervention: SLIT for grass
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SLIT for birch
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SLIT for birch and grass
Number of subjects: 58

Group type: COMPARATOR
Intervention: Drugs only
Number of subjects: 58
Study: 15100593

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (150 mg/day, titrated to 1200 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1200 mg/day during Maintenance Phase)
Number of subjects: 30
Study: 11281158

Group type: EXPERIMENTAL
Intervention: hPTH plus hormone-replacement therapy (HRT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HRT alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: hPTH plus HRT
Number of subjects: 15
Study: 9397118

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with 2 mg/day of oral micronized estradiol for 12 weeks
Number of subjects: 28
Study: 8267176

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasmapheresis before cardiopulmonary bypass (CPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal management without pheresis (Control)
Number of subjects: 40
Study: 3125546

Group type: EXPERIMENTAL
Intervention: Gabexelate mesilate (FOY)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 30943824

Group type: EXPERIMENTAL
Intervention: mHealth tool used by community health workers to calculate CVD risk and confirm physician appointments.
Number of subjects: 755

Group type: COMPARATOR
Intervention: Paper-based tool used by community health workers for screening CVD risk.
Number of subjects: 755
Study: 28840742

Group type: EXPERIMENTAL
Intervention: International Ballroom Dancing (IG) for 10 months
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 129
Study: 25540980

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) diet
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Combination of HP and LGI diets
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: DioGenes diet
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: HP effects after 1 year
Number of subjects: 932
Study: 23561876

Group type: EXPERIMENTAL
Intervention: Core exercise group
Number of subjects: 40
Study: 21642060

Group type: EXPERIMENTAL
Intervention: Hand splint with reflex inhibitory characteristics (worn at least 2 hours each day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no splint)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hand splint with reflex inhibitory characteristics
Number of subjects: 19
Study: 18626487

Group type: EXPERIMENTAL
Intervention: Topical lidocaine jelly
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo jelly
Number of subjects: 25
Study: 17040558

Group type: EXPERIMENTAL
Intervention: MRI examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consultation with an orthopaedic specialist
Number of subjects: 0
Study: 12648114

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation using boluses of propofol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patient-maintained sedation using a target-controlled infusion of propofol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patient-controlled sedation
Number of subjects: 23
Study: 10738427

Group type: EXPERIMENTAL
Intervention: Pneumatic compression devices (pulsatile calf and foot and calf pneumatic compression with rapid inflation time)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pneumatic compression devices (compression of the calf and thigh)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active dorsoplantar flexion
Number of subjects: 10
Study: 8927748

Group type: EXPERIMENTAL
Intervention: Atrophic gastritis in intestinal cancer (distal location)
Number of subjects: 3435

Group type: COMPARATOR
Intervention: Atrophic gastritis in diffuse cancer (tumour-free area)
Number of subjects: 3435

Group type: EXPERIMENTAL
Intervention: Atrophic pangastritis in intestinal distal cancer
Number of subjects: 3435

Group type: COMPARATOR
Intervention: Atrophic pangastritis in diffuse proximal cancer
Number of subjects: 3435

Group type: EXPERIMENTAL
Intervention: Atrophic pangastritis in intestinal proximal cancer
Number of subjects: 3435

Group type: EXPERIMENTAL
Intervention: Atrophic pangastritis in diffuse distal carcinoma
Number of subjects: 3435

Group type: EXPERIMENTAL
Intervention: Atrophic pangastritis association with gastric cancer
Number of subjects: 3435

Group type: EXPERIMENTAL
Intervention: Atrophic pangastritis association with intestinal gastric cancer
Number of subjects: 3435

Group type: EXPERIMENTAL
Intervention: Atrophic pangastritis association with diffuse carcinoma
Number of subjects: 3435
Study: 1425899

Group type: EXPERIMENTAL
Intervention: alfentanil 15 micrograms.kg‐1, vecuronium 0.01 mg.kg‐1, thiopentone 3‐4 mg.kg‐1, suxamethonium 1 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: vecuronium 0.01 mg.kg‐1, thiopentone 3‐4 mg.kg‐1, suxamethonium 1 mg.kg‐1
Number of subjects: 40
Study: 4064558

Group type: EXPERIMENTAL
Intervention: Naloxone (intravenous administration)
Number of subjects: 23
Study: 31167901

Group type: EXPERIMENTAL
Intervention: Pictorial warnings (four versions)
Number of subjects: 876

Group type: COMPARATOR
Intervention: Text-only warning
Number of subjects: 876
Study: 29579308

Group type: EXPERIMENTAL
Intervention: Albendazole plus prednisone
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 173
Study: 27302646

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 206
Study: 24558098

Group type: EXPERIMENTAL
Intervention: Strengths‐Based/Professional Only (PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strengths‐Based/Professional‐Peer (PP)
Number of subjects: 0
Study: 23069487

Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention (alcohol-based hand sanitizer, hand soap, and hand hygiene education)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Usual hand hygiene practices
Number of subjects: 527
Study: 20711087

Group type: EXPERIMENTAL
Intervention: Passive removal of silicone oil with 23-G transconjunctival sutureless system
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20-G active silicone oil removal using all three 20-G ports
Number of subjects: 40
Study: 18652603

Group type: EXPERIMENTAL
Intervention: Adalimumab therapy (160 mg loading dose at week 0, 80 mg at week 2, 40 mg every other week starting at week 4)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Adalimumab therapy
Number of subjects: 13
Study: 15740542

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg, orally, twice daily during antibiotic treatment)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 269
Study: 12093442

Group type: EXPERIMENTAL
Intervention: Acid-induced-viscosity (I-V) complex in glucose beverage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (glucose-based beverage with similar total dietary fiber level and initial viscosity)
Number of subjects: 30
Study: 10657576

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 56
Study: 8777661

Group type: EXPERIMENTAL
Intervention: Commercial sweet-tasting solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 25% sucrose solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50% sucrose solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 60
Study: 1610998

Group type: COMPARATOR
Intervention: Lactated Ringer's (LR) solution (group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LR with 5% dextrose solution (group II)
Number of subjects: 36
Study: 6706438

Group type: EXPERIMENTAL
Intervention: pirbuterol 20 mg
Number of subjects: 16